Cargando…

Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies

Metabolic-associated fatty liver disease (MAFLD) is a new disease definition, and this nomenclature MAFLD was proposed to renovate its former name, non-alcoholic fatty liver disease (NAFLD). MAFLD/NAFLD have shared and predominate causes from nutrition overload to persistent liver damage and eventua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Weiyi, Ma, Tengfei, Cai, Jingjing, Zhang, Xiaojing, Zhang, Peng, She, Zhigang, Wan, Feng, Li, Hongliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568774/ https://www.ncbi.nlm.nih.gov/pubmed/34746195 http://dx.doi.org/10.3389/fmed.2021.761538

Ejemplares similares

Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
por: Sandoval-Rodriguez, Ana, et al.
Publicado: (2022)

Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
por: Dong, Qingfu, et al.
Publicado: (2023)

Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
por: Marc, Luciana, et al.
Publicado: (2022)

MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis
por: Segura-Azuara, Nancy de los Ángeles, et al.
Publicado: (2022)

Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
por: Filipovic, Branka, et al.
Publicado: (2023)

Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022)

COVID-19 and MAFLD/NAFLD: An updated review
por: Nowroozi, Ali, et al.
Publicado: (2023)

Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System
por: Torre, Pietro, et al.
Publicado: (2021)

Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2021)

MAFLD and ASCVD: Plasma Heparin Cofactor II Activity as an Anti-liver Fibrosis Biomarker
por: Shimabukuro, Michio
Publicado: (2023)

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
por: Yang, Zifeng, et al.
Publicado: (2023)

Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
por: Sangro, Paloma, et al.
Publicado: (2023)

Non-pharmacological management options for MAFLD: a practical guide
por: Stefano, José Tadeu, et al.
Publicado: (2023)

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
por: Griffett, Kristine, et al.
Publicado: (2023)

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
por: Yu, Yao, et al.
Publicado: (2018)

Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease
por: Santacroce, Giovanni, et al.
Publicado: (2023)

MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients
por: Chen, Xiaoman, et al.
Publicado: (2022)

The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
por: Abou Assi, Reem, et al.
Publicado: (2021)

MAFLD: an optimal framework for understanding liver cancer phenotypes
por: Crane, Harry, et al.
Publicado: (2023)

Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence
por: Yang, Chenyu, et al.
Publicado: (2022)

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
por: Guo, Qin, et al.
Publicado: (2023)

Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index–related parameters
por: Xue, Yan, et al.
Publicado: (2022)

Molecular Advances in MAFLD—A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis
por: Kołakowski, Adrian, et al.
Publicado: (2022)

Comparison of gut microbiota in male MAFLD patients with varying liver stiffness
por: Zhang, Yuheng, et al.
Publicado: (2022)

MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease
por: Huang, Jiaofeng, et al.
Publicado: (2021)

MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis
por: Huang, Jiaofeng, et al.
Publicado: (2021)

Treatment of liver fibrosis in hepatolenticular degeneration with traditional Chinese medicine: systematic review of meta-analysis, network pharmacology and molecular dynamics simulation
por: Yang, Xulong, et al.
Publicado: (2023)

The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China
por: Lei, Fang, et al.
Publicado: (2022)

NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?—Results From NHANES III
por: Huang, Qi, et al.
Publicado: (2021)

Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
por: Cao, Weijie, et al.
Publicado: (2021)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Role of Insulin Resistance in MAFLD
por: Sakurai, Yoshitaka, et al.
Publicado: (2021)

The Gut Microbiome and Ferroptosis in MAFLD
por: Ji, Jie, et al.
Publicado: (2023)

MAFLD: a multisystem disease
por: Pipitone, Rosaria Maria, et al.
Publicado: (2023)

NAFLD/MAFLD: New Evidence
por: Mantovani, Alessandro, et al.
Publicado: (2023)

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

MAFLD and Celiac Disease in Children
por: Scapaticci, Serena, et al.
Publicado: (2023)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
por: Kawaguchi, Takumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b7bjli8elkoa7ehli8196kr36h